HSD17B13 and metabolic dysfunction-associated steatotic liver disease: Also, the magnitude of change in ALT is small relative to that associated with variants in PNPLA3, HSD17B13, mitochondrial amidoxime reducing component 1 (MTARC1), and TM6SF2. This might account for the absence of this variant (or others near MBOAT7) from GWAS for NAFLD in the general population.1